| Diabetic Retinopathy
Iluvien vs Susvimo
Side-by-side clinical, coverage, and cost comparison for diabetic retinopathy.Deep comparison between: Iluvien vs Susvimo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSusvimo has a higher rate of injection site reactions vs Iluvien based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Susvimo but not Iluvien, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Iluvien
Susvimo
At A Glance
Intravitreal injection
Corticosteroid
Ocular implant (intravitreal)
Every 24-36 weeks
VEGF-A antagonist
Indications
- Diabetic Retinopathy
- Uveitis
- Wet age-related macular degeneration
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
Dosing
Diabetic Retinopathy, Uveitis Single 0.19 mg (190 mcg) fluocinolone acetonide intravitreal implant injected under aseptic conditions via a preloaded single-use applicator; optimal placement is inferior to the optic disc and posterior to the equator, with needle entry 4 mm inferotemporal from the limbus.
Wet age-related macular degeneration, Macular edema due to diabetes mellitus 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills every 24 weeks (approximately 6 months).
Diabetic Retinopathy 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills every 36 weeks (approximately 9 months).
Contraindications
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratio greater than 0.8
- Known hypersensitivity to any components of ILUVIEN
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to ranibizumab products or any excipient in SUSVIMO
Adverse Reactions
Most common (>=1%) Cataract, increased intraocular pressure, myodesopsia, eye pain, conjunctival haemorrhage, posterior capsule opacification, eye irritation, vitreous detachment, conjunctivitis, corneal oedema, ocular hyperaemia, anemia, headache, renal failure, pneumonia
Serious Optic nerve damage, visual acuity and field defects, secondary ocular infections including herpes simplex, perforation of the globe where there is thinning of the cornea or sclera
Postmarketing Drug administration error, drug ineffectiveness
Most common (>=10%) Conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, cataract, conjunctival disorder, vitreous hemorrhage
Serious Endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion or retraction, conjunctival bleb, postoperative decrease in visual acuity
Pharmacology
Fluocinolone acetonide is a synthetic corticosteroid that inhibits inflammatory responses by blocking phospholipase A2 via lipocortins, suppressing biosynthesis of prostaglandins and leukotrienes and reducing edema, leukocyte migration, capillary proliferation, and fibroblast proliferation.
Ranibizumab is a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to multiple biologically active forms of VEGF-A, blocking interaction with VEGFR1 and VEGFR2 on endothelial cells and thereby inhibiting neovascularization and vascular leakage.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Iluvien
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Susvimo
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Iluvien
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Susvimo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Iluvien
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Susvimo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25
Iluvien CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IluvienView full Iluvien profile
SusvimoView full Susvimo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.